Researchers from the Departments of Cell Biology and Medical Physiology at the University of Seville have identified that a high expression of the human protein VRK1 is associated with tumor aggressiveness and low survival ...
Dec 11, 2020
0
4
A novel CAR T-cell therapy developed by researchers at UCL and designed to target cancerous tumors, has shown promising early results in children with neuroblastoma, a rare form of childhood cancer.
Nov 25, 2020
0
33
October 14, 2020) Researchers have used insight from a comprehensive genomic analysis of neuroblastoma to learn about the process driving one of the most common childhood solid tumors. The findings revealed possible approaches ...
Oct 15, 2020
0
7
A drug has shown great promise in the treatment of neuroblastoma, an aggressive form of childhood cancer. The study was led by researchers at Lund University in Sweden, and is published in the journal Science Translational ...
Oct 6, 2020
0
9
An aggressive form of the childhood cancer neuroblastoma could be treatable with two cancer drugs currently used in the treatment of colon and ovarian cancer, a study led by researchers at The Institute of Cancer Research, ...
Sep 29, 2020
0
4
A type of drug known as a PARP inhibitor, already used to treat breast and ovarian cancer, may be useful in treating children with high-risk neuroblastoma—a common childhood tumor with a low survival rate.
Jun 25, 2020
0
6
Researchers from Kanazawa University retrospectively analyzed children with refractory or relapsed high-risk neuroblastoma who were treated with high-dose 131I-metaiodobenzylguanidine at Kanazawa University Hospital. They ...
Jun 19, 2020
0
1
Neuroblastoma is a devastating solid tumor of childhood and emerges in the sympathetic nervous system while many kids who develop it are still toddlers.
In a new paper published March 5 in the journal Cell Stem Cell, researchers in Whitehead Institute Member Rudolph Jaenisch's lab introduce a new way to model human neuroblastoma tumors in mice using chimeras—in this case, ...
Mar 6, 2020
1
165
A research group led by Professor NISHIMURA Noriyuki (Graduate School of Health Sciences, Kobe University) has developed a new method to monitor the residual disease after treatment in high-risk neuroblastoma patients. The ...
Feb 7, 2020
0
4
